Corpus ID: 8811783

Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.

@article{Lee2002UseOZ,
  title={Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.},
  author={Yu-Po Lee and Edward M. Schwarz and Mark R Davies and Mark Jo and Jeffrey Gates and Xuguang Zhang and Jing Wu and Jay R. Lieberman},
  journal={Cancer research},
  year={2002},
  volume={62 19},
  pages={
          5564-70
        }
}
Prostate adenocarcinoma is associated with the formation of osteoblastic metastases in bone. It has been hypothesized that osteoclastic bone resorption is a critical component before the development of these osteoblastic lesions in bone. This observation has led researchers to test agents that inhibit osteoclastic activity to prevent or halt the formation of metastatic prostate cancer lesions in bone. Bisphosphonates inhibit osteoclast activity, and previous studies showed that they have the… Expand
Zoledronic Acid Inhibits Both the Osteolytic and Osteoblastic Components of Osteosarcoma Lesions in a Mouse Model
TLDR
The data show that clinically relevant doses of ZOL, while protecting the bone from OS-induced bone destruction, do not inhibit primary tumor growth, indicating that caution is required when the clinical application of the bisphosphonate class of antiresorptives is considered in OS. Expand
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
TLDR
The combination of ZOL and IFO was more effective than each agent alone in preventing tumor recurrence, improving tissue repair, and increasing bone formation as revealed by the analysis of trabecular architecture. Expand
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft
TLDR
A potential role for OPG is suggested in the treatment of established osteoblastic CaP bone metastases in an animal model using LuCaP 23.1 cells as a model for evaluating serum prostate specific antigen (PSA). Expand
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone
TLDR
The results indicate that in vivo RANK blockade may not be effective for the prevention of osteoblastic metastasis but may potentially represent a novel therapy that limits the growth of established metastatic CaP lesions in bone. Expand
The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
TLDR
Results suggest that YM529 may inhibit cancer cell invasion into the bone matrix by repressing the expression of CXCR-4 in bone metastasis lesions. Expand
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
TLDR
The use of the osteolysis-inhibitory agent ZOL in combination with docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option. Expand
Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
TLDR
BMPs influence the formation of the osteolytic prostate cancer metastases, and treatment modalities that inhibit BMP activity may limit the progression of the lytic component of prostatecancer metastases. Expand
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions
TLDR
This study hypothesized that tumor‐induced osteolysis promoted the incidence of bone metastases and osteoblastic activity and established a nude mouse model with mixed bone metastasis using intracardiac injection of canine prostate cancer cells. Expand
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis
TLDR
Tumour growth in this model of osteosclerotic metastasis is dependent on ongoing bone resorption, as has been observed in osteolytic models, and correction of calcium deficiency and/or with anti-resorptive agents such as OPG may improve patient outcomes in the adjuvant as well as palliative settings. Expand
Lack of prophylactic effect of incadronate on skeletal lesions associated with implants of prostate cancer.
TLDR
Results indicate that application of BP alone is not sufficient to prevent skeletal lesions due to CaP in patients with high risk of bone metastases although it is useful in inhibition of cancer-induced bone resorption with osteoblastic changes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 37 REFERENCES
Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
TLDR
It was observed that intravenous therapy was associated with a decrease in bone pain in 76% of patients and a reduction in the use of analgesics, and the clinical response appeared to parallel the biochemical changes in bone resorption. Expand
Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone
TLDR
The results suggest that the role of the osteoclast in the development of a metastatic lesion is variable depending on the phenotype of the prostate cancer cells, and that tumor‐induced osteolysis may not be required for osteoblastic metastases. Expand
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.
TLDR
It is demonstrated that CaP cells directly induce osteoclastogenesis from osteocline precursors in the absence of underlying stroma in vitro, which emphasizes the important role that osteOClast activity plays in the establishment of CaP skeletal metastases, including those with an osteoblastic component. Expand
Effects of two novel bisphosphonates on bone cells in vitro.
TLDR
Investigation of the effects of two novel bisphosphonates on osteoclastogenesis in fetal rat calvariae cultured on collagen gels and on human osteoblasts cultured as explants from bone taken from patients at surgery demonstrates that all three bisph phosphonates are able to inhibit osteOClast formation at low concentrations. Expand
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
TLDR
Evidence that BP pretreatment of breast and prostate carcinoma cells inhibited tumor cell invasion in a dose-dependent manner is provided and BPs may be useful agents for the prophylactic treatment of patients with cancers that are known to preferentially metastasize to bone is suggested. Expand
Bisphosphonates and breast carcinoma
The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate bone metastases at autopsy. The lytic destruction of bone in these patients is due toExpand
Mechanisms of lytic and blastic metastatic disease of bone.
  • C. Galasko
  • Medicine
  • Clinical orthopaedics and related research
  • 1982
TLDR
In the vast majority of skeletal metastases bone destruction is associated with reactive new bone formation, similar to callus associated with fracture repair, and myelomata and lymphomata are not associated with this reactivenew bone formation. Expand
Markers of bone turnover for the management of patients with bone metastases from prostate cancer
TLDR
Comparing the clinical utility of new bone resorption markers to that of bone formation in patients with bone metastases from prostate cancer before and after bisphosphonate treatment suggests that these new resOrption markers may be useful for the management of these patients. Expand
Effects of short‐term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: A comparative histomorphometric study on the cancellous bone formed before, during, and after treatment
TLDR
The bone formed before, during, and after treatment with bisphosphonates responds differently due to differences in bone architecture, rates of modeling and remodeling, and period of drug exposure. Expand
Mechanisms of the development of osteoblastic metastases
TLDR
Each site of molecular interaction in the mechanisms of interaction of prostate carcinoma and other cancers with bone may provide a therapeutic window for curtailing the effects of these tumors on the skeleton. Expand
...
1
2
3
4
...